Malaria vaccines: multiple targets.

[1]  S. Hoffman,et al.  Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. , 1993, The American journal of tropical medicine and hygiene.

[2]  B. Chait,et al.  Structural and functional properties of region II-plus of the malaria circumsporozoite protein , 1994, The Journal of experimental medicine.

[3]  A. Holder,et al.  Immunization against malaria with a recombinant protein , 1994, Parasite immunology.

[4]  V. Nussenzweig,et al.  Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria , 1990, The Journal of experimental medicine.

[5]  J. Playfair,et al.  The malaria vaccine: anti-parasite or anti-disease? , 1990, Immunology today.

[6]  T. Daly,et al.  A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice , 1993, Infection and immunity.

[7]  D. Clyde,et al.  Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. , 1975, The American journal of tropical medicine and hygiene.

[8]  Pedro Romero,et al.  A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria , 1988, Nature.

[9]  W. Trager,et al.  Cultivation of malarial parasites , 1978, Nature.

[10]  V. Nussenzweig,et al.  The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of plasmodium falciparum sporozoites , 1992, Cell.

[11]  Myron M. Levine,et al.  Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites , 1987, Nature.

[12]  A. Moreno,et al.  Immunization of owl monkeys with a combination of Plasmodium falciparum asexual blood-stage synthetic peptide antigens. , 1990, The American journal of tropical medicine and hygiene.

[13]  V. Nussenzweig,et al.  Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes , 1993, The Journal of experimental medicine.

[14]  S. Herrera,et al.  Failure of a synthetic vaccine to protect Aotus lemurinus against asexual blood stages of Plasmodium falciparum. , 1992, The American journal of tropical medicine and hygiene.

[15]  D. Herrington,et al.  Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. , 1991, The American journal of tropical medicine and hygiene.

[16]  A. Holder.  The precursor to major merozoite surface antigens: structure and role in immunity. , 1988, Progress in allergy.

[17]  K. Sell,et al.  Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. , 1974, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[18]  P. Palese,et al.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  E. Nardin,et al.  Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein , 1991, European journal of immunology.

[20]  J. Vanderberg,et al.  Immunization of man against sporozite-induced falciparum malaria , 1973, The American journal of the medical sciences.

[21]  D. Weatherall,et al.  Erythrocytes deficient in glycophorin resist invasion by the malarial parasite Plasmodium falciparum , 1982, Nature.

[22]  P. Barr,et al.  Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant , 1993, Infection and immunity.

[23]  J. Ou,et al.  Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. , 1988, Science.

[24]  P. Bloland,et al.  Brief report: malaria probably locally acquired in New Jersey. , 1994, The New England journal of medicine.

[25]  E. Nardin,et al.  T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. , 1993, Annual review of immunology.

[26]  P. Romero,et al.  The in vivo cytotoxic activity of CD8+ T cell clones correlates with their levels of expression of adhesion molecules , 1992, The Journal of experimental medicine.

[27]  E. Cabib,et al.  Malaria parasite chitinase and penetration of the mosquito peritrophic membrane. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Kaslow,et al.  Transmission-blocking activity of a chitinase inhibitor and activation of malarial parasite chitinase by mosquito protease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Kaslow.  Transmission-blocking immunity against malaria and other vector-borne diseases. , 1993, Current opinion in immunology.

[30]  R. Campenot,et al.  Concentration-dependent regulation of neuronal gene expression by nerve growth factor , 1992, The Journal of cell biology.

[31]  W. Trager,et al.  Human malaria parasites in continuous culture. , 1976, Science.

[32]  M. Good,et al.  CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Waters,et al.  Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen , 1988, Parasite immunology.

[34]  J. Haynes,et al.  Evidence for differences in erythrocyte surface receptors for the malarial parasites, Plasmodium falciparum and Plasmodium knowlesi , 1977, The Journal of experimental medicine.

[35]  V. Nussenzweig,et al.  Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria , 1989, Nature.

[36]  C. Long,et al.  Immunity to blood stages of malaria. , 1993, Current opinion in immunology.

[37]  P. Alonso,et al.  Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia , 1993, The Lancet.

[38]  M. Patarroyo,et al.  Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years. , 1992, Vaccine.

[39]  I. Sherman,et al.  Synthetic peptides based on motifs present in human band 3 protein inhibit cytoadherence/sequestration of the malaria parasite Plasmodium falciparum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  V. Nussenzweig,et al.  γ Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites , 1987, Nature.

[41]  V. Nussenzweig,et al.  Rationale for the development of an engineered sporozoite malaria vaccine. , 1989, Advances in immunology.